RXK3 Stock Overview A late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
SELLAS Life Sciences Group, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for SELLAS Life Sciences Group Historical stock prices Current Share Price US$0.94 52 Week High US$1.64 52 Week Low US$0.45 Beta 2.41 1 Month Change -13.28% 3 Month Change -11.49% 1 Year Change 82.52% 3 Year Change -80.63% 5 Year Change -65.19% Change since IPO -99.66%
Recent News & Updates
SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia Dec 11
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AML Dec 10
SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers Nov 28
New major risk - Financial position Nov 15
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia Oct 15 SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million. Aug 02
See more updates
SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia Dec 11
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AML Dec 10
SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers Nov 28
New major risk - Financial position Nov 15
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia Oct 15 SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million. Aug 02
SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million. Aug 01
SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia Jul 08
SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia Jun 25
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia Jun 18
New major risk - Financial position May 16
SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level May 03
SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024 May 01
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study Apr 30
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML Mar 26
New major risk - Shareholder dilution Mar 20 SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million. Mar 20
SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering. Mar 16
SELLAS Life Sciences Group, Inc. Announces Executive Changes Mar 08
SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Feb 17
SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients Jan 10 SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million. Jan 05
SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma Dec 28
Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia Dec 15
SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market Dec 09
Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia Dec 05
SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia Nov 29
SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S Nov 14
New major risk - Negative shareholders equity Nov 11
SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting Nov 07
New major risk - Shareholder dilution Nov 04
SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia Oct 17
SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia Oct 15
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas Oct 12
New major risk - Share price stability Oct 11
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data in Lymphoma Cohort from Sls009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met Sep 22
New major risk - Financial position Jul 03
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma Jun 29
Sellas Life Sciences Group, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial of GFH009 in Acute Myeloid Leukemia Jun 23
Sellas Life Sciences Group, Inc. Announces Positive Topline Data from Gfh009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study May 05
Full year 2022 earnings released: US$2.13 loss per share (vs US$1.34 loss in FY 2021) Mar 18
SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial Officer Feb 07
SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality Jan 06
SELLAS Life Sciences Group, Inc. Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies Dec 15
SELLAS Life Sciences Group, Inc. ’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned Dec 10
SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vivo Study Dec 02
Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021) Nov 16
Insufficient new directors Nov 16
SELLAS Life Sciences Group, Inc. Announces Update on Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia Nov 15
SELLAS Life Sciences Group, Inc. Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (Pembrolizumab) in Patients with Wt1+ Platinum-Resistant Advanced Ovarian Cancer Nov 11
SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S Oct 12
Insufficient new directors Sep 09
SELLAS Life Sciences Group Announces Results from New Preclinical in Vitro Study for its Highly Selective CDK9 Inhibitor, GFH009 Aug 25
SELLAS Life Sciences Group, Inc. Announces Election of Katherine Bach Kalin to Its Board of Directors Aug 17
Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.30 loss in 2Q 2021) Aug 13
SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vitro Studies for CDK9 inhibitor, GFH009 Aug 11
SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009 Jul 08
SELLAS Life Sciences Group, Inc. Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial Jun 28
SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo Jun 09
SELLAS Life Sciences Group, Inc. Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer May 27
First quarter 2022 earnings released: US$1.05 loss per share (vs US$0.16 loss in 1Q 2021) May 14
Insufficient new directors Apr 27
SELLAS Life Sciences Group, Inc. Launches Expand Access Program for Galinpepimut-S Apr 27
SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 08, 2022 Apr 26
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study Apr 12
Sellas Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China Apr 07
Sellas Life Sciences Group, Inc. Announces Final Court Approval of Settlement of Securities Litigation Mar 01
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer Feb 02
SELLAS Life Sciences Group, Inc. Announces IND Acceptance for First Clinical Trial of GPS in China Jan 27
SELLAS Life Sciences Group, Inc. Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer Jul 01
SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo Jun 25
Forecast breakeven pushed back to 2024 May 24
Forecast breakeven pushed back to 2024 May 15
Sellas Life Sciences Group, Inc. Announces Executive Changes Feb 05
Sellas Life Sciences Group, Inc. Announces Promising Initial Clinical Data for Galinpepimut-S (Gps) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications Dec 23
SELLAS Life Sciences Group, Inc. Announces Positive Follow-Up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast Dec 13
SELLAS Life Sciences Group, Inc. and SLSG Limited, LLC Enter into an Exclusive License Agreement with 3D Medicines Inc Dec 12
Sellas Life Sciences Group, Inc and 3D Medicines Inc. Announces to Enters into an Exclusive License Agreement Dec 10
New 90-day high: €3.34 Dec 08
New 90-day high: €2.38 Nov 19
New 90-day low - €2.31 Aug 19 Shareholder Returns RXK3 DE Biotechs DE Market 7D 2.8% 6.0% 1.7% 1Y 82.5% -5.6% 9.4%
See full shareholder returns
Return vs Market: RXK3 exceeded the German Market which returned 9.6% over the past year.
Price Volatility Is RXK3's price volatile compared to industry and market? RXK3 volatility RXK3 Average Weekly Movement 13.7% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: RXK3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RXK3's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials.
Show more SELLAS Life Sciences Group, Inc. Fundamentals Summary How do SELLAS Life Sciences Group's earnings and revenue compare to its market cap? RXK3 fundamental statistics Market cap €71.65m Earnings (TTM ) -€31.30m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RXK3 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$32.28m Earnings -US$32.28m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 15:48 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources SELLAS Life Sciences Group, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Li Wang Watsek Cantor Fitzgerald & Co. Joseph Pantginis H.C. Wainwright & Co.
Show 3 more analysts 
